Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib + vinorelbine-based regimens in HER2-positive metastatic breast cancer
ChiCTR2600127696Phase 4Not yet recruiting
- Sponsor
- Shanghai GoBroad Cancer Hospital
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of neratinib in HER2-enriched breast cancer (HER2+) (2 cohorts), sponsored by Shanghai GoBroad Cancer Hospital. Primary endpoint: Progression-Free Survival. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
neratinib
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on ChiCTR2600127696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127696.